Urmila Chandran

Johnson & Johnson (United States)

Papers

1

Total Citations

66

H-Index

1

About

Dr. Urmila Chandran is a leading epidemiologist and health outcomes researcher whose work focuses on cancer survivorship, recurrence patterns, and long-term outcomes in non-small cell lung cancer (NSCLC). Her landmark 2023 study on recurrence-free survival (RFS) in surgically resected NSCLC patients has garnered 66 citations, providing a critical summary estimate that fills a significant gap in the literature. This work systematically quantified post-surgical recurrence risks, offering clinicians and patients evidence-based benchmarks for prognosis and follow-up care. Dr. Chandran’s research is distinguished by its rigorous synthesis of real-world data, directly informing surveillance strategies and adjuvant therapy decisions. Her contributions have been instrumental in shifting the conversation from mere survival to recurrence-free survival as a key endpoint in NSCLC management. With a career dedicated to translating clinical questions into actionable evidence, Dr. Chandran continues to shape standards in thoracic oncology, empowering researchers and practitioners to improve long-term outcomes for lung cancer patients.

Research Focus

Key Achievements

1
H-Index
1
Papers
66
Total Citations
66
Avg Citations/Paper
🏆 Most Cited Paper
Recurrence-Free Survival in Patients With Surgically Resected Non-Small Cell Lung Cancer
66 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 8
🏛 Institutions: Johnson & Johnson (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago